Articles scientifiques

Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy.

Auteurs : Latifyan S, Genot MT, Klastersky J
Année : 2016
Journal : Support Care Cancer
Volume : 24(9)
Pages : 3687-93

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Auteurs : Hortobagyi GN, Chen D, Piccart-Gebhart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J
Année : 2016
Journal : J Clin Oncol
Volume : 34(5)
Pages : 419-26

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.

Auteurs : Lambertini M, Pinto AC, Ameye L, Jongen L, Del Mastro L, Puglisi F, Poggio F, Bonotto M, Floris G, Van Asten K, Wildiers H, Neven P, de Azambuja E, Paesmans M, Azim HA Jr
Année : 2016
Journal : Br J Cancer
Volume : 115(12)
Pages : 1471-78

Adjuvant systemic therapy in breast cancer: quo vadis?

Auteurs : Sonnenblick A, Piccart-Gebhart M
Année : 2015
Journal : Ann Oncol
Volume : 26(8)
Pages : 1629-34

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.

Auteurs : Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart M, Scaltriti M, Baselga J
Année : 2015
Journal : Ann Oncol
Volume : 26
Pages : 1494-500

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

Auteurs : Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair O, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber Rd, Godhirsch A, Korde L, Azim HA, Partridge AH
Année : 2015
Journal : Breast
Volume : 24(3)
Pages : 201-7

Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.

Auteurs : de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Hernández SB, Shih-Li C, Delhaye F, Focan C, Cornez N, Vindevoghel A, Beauduin M, Lemort M, Paesmans M, Suter T, Piccart-Gebhart M
Année : 2015
Journal : Eur J Cancer
Volume : 51
Pages : 2517-24

Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy.

Auteurs : Azim HA, Vingiani A, Peccatori F, Viale G, Loi S, Pruneri G
Année : 2015
Journal : Breast
Volume : 24(3)
Pages : 290-3

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib.

Auteurs : Draganova D, Kerger J, Caspers L, Willermain F
Année : 2015
Journal : J Ophthalmic Inflamm Infect
Volume : 5
Pages : 17

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

Auteurs : Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart-Gebhart M, Baselga J
Année : 2015
Journal : Clin Cancer Res
Volume : 21(3)
Pages : 569-76

Vulvar metastasis from bladder cancer.

Auteurs : Aoun F, El Rassy E, Kourie HR, Hawaux E, Van Velthoven R
Année : 2015
Journal : Case Rep Obstet Gynecol
Volume : 2015
Pages : 324634

Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.

Auteurs : Gombos A, Barthélémy P, Awada A
Année : 2015
Journal : Expert Opin Drug Metab Toxicol
Volume : 11(5)
Pages : 823-34.

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.

Auteurs : Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA, Ugolini D, Pronzato P, Loibl S, Moore HC, Partridge AH, Bruzzi P, Del Mastro L
Année : 2015
Journal : Ann Oncol
Volume : 26
Pages : 2408-19

Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?

Auteurs : Azim HA
Année : 2015
Journal : Ann Oncol
Volume : 26(8)
Pages : 1521-3

New generations of targeted therapies fighting the resistance in solid tumors.

Auteurs : Barthélémy P, Aftimos P, Awada A
Année : 2015
Journal : Curr Opin Oncol
Volume : 27(3)
Pages : 243-9

What can be learned from our pediatric colleagues?

Auteurs : Klastersky J
Année : 2015
Journal : Curr Opin Oncol
Volume : 27
Pages : 283-4

Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer.

Auteurs : Zardavas D, Piccart-Gebhart M
Année : 2015
Journal : Am Soc Clin Oncol Educ Book
Volume : 35
Pages : e183-90

Metabolic disorders associated with the use of targeted cancer therapies.

Auteurs : Kotecki N, Penel N, Awada A
Année : 2015
Journal : Curr Opin Oncol
Volume : 27(3)
Pages : 258-66

Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.

Auteurs : Gingras I, Azim HA Jr, Ignatiadis M, Sotiriou C
Année : 2015
Journal : Clin Adv Hematol Oncol
Volume : 13
Pages : 372-82

Tailoring therapies - improving the management of early breast cancer: St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Auteurs : Coates AS, Winer EP, Goldhirsch A, Gelber Rd, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ
Année : 2015
Journal : Ann Oncol
Volume : 26(8)
Pages : 1533-46